Lenamilast - Suzhou Intragrand Pharma
Alternative Names: ITG-1052Latest Information Update: 04 Jul 2025
At a glance
- Originator Suzhou Intragrand Pharma
- Class Antifibrotics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis; Unspecified
Most Recent Events
- 12 Jun 2025 SUZHOU INTRAGRAND PHARMA has patents pending for 'Substituted Isoindoline-1, 3-diketone PDE4 Inhibitor and Pharmaceutical Application Thereof' in USA
- 03 Jun 2025 ITG-1052 licensed to Transpire Bio worldwide except China
- 03 Jun 2025 Early research in Idiopathic pulmonary fibrosis in China (Inhalation) prior to June 2025